Back to top

Analyst Blog

Celgene Corporation (CELG - Analyst Report) announced that encouraging data from a phase III study (MPACT: n=861) on its oncology drug Abraxane was published at the New England Journal of Medicine. The study evaluated the combination of Abraxane and Eli Lilly and Company’s (LLY - Analyst Report) Gemzar as a first-line therapy in patients suffering from metastatic adenocarcinoma of the pancreas.

We remind investors that encouraging data from the MPACT study formed the basis of the U.S. approval of Abraxane in the pancreatic cancer indication. The U.S. Food and Drug Administration (FDA) approved Abraxane for the above indication in Sep 2013. The FDA clearance marks the first approval of a drug for the metastatic pancreatic cancer indication in nearly eight years.

We note that Abraxane in combination with Gemzar is also under review in the EU for the advanced pancreatic cancer indication. Abraxane is also under review in many other countries for the indication.

We note that this is the third indication for which Abraxane has been approved. Abraxane is already available as a second-line therapy for metastatic breast cancer. Last year, the drug was cleared by the FDA as a first-line combination therapy for treating patients suffering from locally advanced or metastatic non-small cell lung cancer. The FDA approval for the advanced pancreatic cancer indication has boosted the drug’s sales potential.

Celgene, a biopharmaceutical company, currently carries a Zacks Rank #3 (Hold). Biopharma stocks like Actelion Ltd. (ALIOF) and Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) appear to be more attractive. Actelion carries a Zacks Rank #1 (Strong Buy) while Alexion is a Zacks #2 Ranked (Buy) stock.

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SUPER MICRO… SMCI 27.00 +10.25%
CANADIAN SO… CSIQ 38.34 +8.18%
CENTURY ALU… CENX 26.97 +7.97%
WILLDAN GRO… WLDN 11.38 +5.86%
AROTECH COR… ARTX 3.78 +5.59%